Examining amino acid loss in patients undergoing kidney treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the loss of amino acids during continuous renal replacement therapy (CRRT) in intensive care patients. It will measure amino acid concentrations in both the effluent from the CRRT machine and the plasma of patients receiving CRRT, as well as in a control group of patients not undergoing this therapy. The study will involve 20 patients on CRRT and 10 patients without renal replacement therapy, assessing changes in amino acid levels over time and monitoring various health parameters. The findings could provide insights into nutritional management for patients with renal insufficiency.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Postoperative ICU patients
* Age ≥ 18 years
* Patients on enteral or/and parenteral nutrition given according to internal standard operating procedure

A) CRRT group:

\- CRRT treatment planned; all types of CRRT (continuous veno-venous hemodialysis (CVVHD), continuous veno-venous hemodiafiltration (CVVHDF), continuous veno-venous hemofiltration (CVVH))

B)Non-CRRT group:

* no current or previous (\<30 days) continuous or intermittent RRT
* no chronic kidney disease stage G3-G5

Exclusion criteria:

* Preoperative intensive care patients
* Patients with liver cirrhosis stage 1-3 according to the Child-Pugh classification
* Patients with acute liver failure

Where it's running

• Medical University of Vienna
  Vienna, State of Vienna, Austria Recruiting

Study contacts

• Principal investigator: Sarah Yadavalli, Dr. — Medical University of Vienna
• Study coordinator: Sarah Yadavalli, Dr.
• Email: sarah.yadavalli@meduniwien.ac.at
• Phone: +43 67761632558

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)

  This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.

  Recruiting Vivalyx GmbH · Rotterdam · NCT07792317

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Kidney and liver blood flow patterns after major trauma

  We will use bedside ultrasound to see whether abnormal kidney and liver blood flow patterns occur in adults admitted to the ICU after major trauma and whether those patterns link to acute kidney injury or the need for mechanical ventilation.

  Recruiting Azienda Usl di Bologna · Bologna · NCT07492511

• Home-based exercise to boost fitness for people waiting for a kidney transplant

  This study tests whether a 12-week, home-based exercise program plus a wearable activity tracker helps adults on the kidney transplant waiting list increase daily activity and improve physical function.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07446296

• CRISPR-edited donor kidney transplant to reduce rejection risk

  This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053462

• Single 3 mg Azvudine safety and blood-level test for adults with mild-to-moderate kidney decline and healthy adults

  This trial gives a single 3 mg dose of Azvudine to adults with mild-to-moderate kidney function decline and to healthy adults to test how the body handles the drug and whether it is safe.

  Recruiting Phase 1 Henan Genuine Biotech Co., Ltd. · Beijing, Beijing Municipality · NCT07001436

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.